One “misunderstood” health issue: demonstrating and communicating the safety of influenza a vaccination in pregnancy: a systematic review and meta-analysis

摘要

The American College of Obstetricians and Gynecologists (ACOG) makes certain recommendations including the annual influenza vaccination of pregnant and pre-pregnant women during influenza (flu) season with an inactivated influenza vaccine as soon as it becomes available. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices in association with ACOG state that the vaccine is safe to be given any trimester during pregnancy. However, due to a lack of communication, the public is unaware of the effects of influenza A vaccination in pregnancy. Since this is a vital public health concern, we aimed to communicate with evidence, the safety of influenza A vaccination in pregnancy in order to improve the rate of influenza A vaccines in pregnant women. This health communication issue was based on the impact of influenza vaccine on fetal outcomes. Therefore, a search was carried out through medical-based online databases including: Cochrane Central, EMBASE, Web of Science, MEDLINE, http://www.ClinicalTrials.gov , and Google scholar for relevant English-based publications. Adverse fetal outcomes were considered as the endpoints of this analysis. The most specific RevMan 5.3 (latest version) software was used to carry out this analysis. Risk ratios (RR) with 95% confidence intervals (CI) were involved in data and results representation and interpretation. A total number of 679, 992 pregnant women participated in this analysis. Based on this current analysis, premature/preterm birth (?37?weeks) was significantly reduced in pregnant women who were vaccinated for influenza A (RR: 0.80, 95% CI: 0.69–0.92; P?=?0.002) as compared to those women who were not vaccinated. Similarly, influenza A vaccination decreased the risk for very preterm birth (?32?weeks) (RR: 0.70, 95% CI: 0.58–0.84; P?=?0.0001). The risks for infants with low birth weight (RR: 0.71, 95% CI: 0.49–1.04; P?=?0.08), very low birth weight (RR: 0.69, 95% CI: 0.23–2.11; P?=?0.52) and infants small for gestational age (RR: 0.93, 95% CI: 0.83–1.05; P?=?0.26) were not increased with the vaccine. Influenza A vaccination was not associated with increased risks of stillbirth (RR: 0.63, 95% CI: 0.38–1.03; P?=?0.07), birth defects (RR: 0.67, 95% CI: 0.26–1.72; P?=?0.41), admission to neonatal intensive care unit or Apgar score??7 in 5?min. Influenza vaccine is completely safe in pregnancy. It significantly lowers premature birth and is not associated with any serious adverse neonatal outcome. Hence, this important piece of information should be communicated and conveyed to all pregnant women, for a safer and healthier pregnancy. At last, this public health issue should further be addressed to the population through media and other communication means in order to improve the rate of influenza A vaccines in pregnant women for a healthier and more productive population.